- Home
- TSVT vs TERN Comparison
TSVT vs TERN Comparison
Compare TSVT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- TERN
- Stock Information
- Founded
- TSVT 2021
- TERN 2017
- Country
- TSVT United States
- TERN United States
- Employees
- TSVT N/A
- TERN N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- TERN Health Care
- Exchange
- TSVT Nasdaq
- TERN Nasdaq
- Market Cap
- TSVT 258.9M
- TERN 298.1M
- IPO Year
- TSVT N/A
- TERN 2021
- Fundamental
- Price
- TSVT $4.98
- TERN $2.40
- Analyst Decision
- TSVT Buy
- TERN Buy
- Analyst Count
- TSVT 4
- TERN 5
- Target Price
- TSVT $6.50
- TERN $18.38
- AVG Volume (30 Days)
- TSVT 1.1M
- TERN 1.3M
- Earning Date
- TSVT 05-07-2025
- TERN 05-12-2025
- Dividend Yield
- TSVT N/A
- TERN N/A
- EPS Growth
- TSVT N/A
- TERN N/A
- EPS
- TSVT N/A
- TERN N/A
- Revenue
- TSVT $37,862,000.00
- TERN N/A
- Revenue This Year
- TSVT $84.48
- TERN N/A
- Revenue Next Year
- TSVT $9.69
- TERN N/A
- P/E Ratio
- TSVT N/A
- TERN N/A
- Revenue Growth
- TSVT N/A
- TERN N/A
- 52 Week Low
- TSVT $2.29
- TERN $1.87
- 52 Week High
- TSVT $5.30
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- TSVT 76.79
- TERN 40.98
- Support Level
- TSVT $4.88
- TERN $2.22
- Resistance Level
- TSVT $4.99
- TERN $2.43
- Average True Range (ATR)
- TSVT 0.03
- TERN 0.24
- MACD
- TSVT -0.08
- TERN 0.04
- Stochastic Oscillator
- TSVT 90.91
- TERN 52.71
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.